Widespread to Targeted Screening

Medical science has shown that some people are more likely to develop certain types of cancer than others. Women over 50, for instance, are at higher risk of developing breast cancer than women in their 20s and 30s. Men are more likely to die from colon cancer than women, and people from certain ethnic backgrounds are more likely to develop colon cancer than others. However, that doesn't mean that people at low risk don't develop certain types of cancer. Thus, many researchers aim to create tools that would start by identifying the risk levels of large groups of people, sift the people with the highest risk levels from those with the lowest risk levels, and then focus on early screening and testing of people who are most likely to develop cancer.

Algorithmic screening is one tool many doctors are using in screening trials. AI can analyze large amounts of patient data at once to determine the likelihood of a person developing a certain type of cancer at any point in time. Those who are less likely to develop cancer (even if they are in what's considered to be an "at-risk" age, gender, or ethnic group) would not need screening as often as someone who is at high risk.

Genetic screening trials, on the other hand, have two main goals. Some researchers are looking for more cancer-causing genes with the end goal of identifying high-risk people sooner than is currently possible. Others are focused on screening trials that can make genetic testing more widespread than it currently is. Again, the goal is to test not just people who are known to be at risk for family cancer but also those who aren't in an "at-risk" group. Blood, saliva, urine, and liquid biopsy screenings are used for this purpose, with the end goal being to find the people who have the highest risk levels and recommend further and more regular testing for people in this group.

General Screening for Everyone

MCED testing, on the other hand, is designed for use on people of all ages and walks of life, even if they aren't at high-risk of developing cancer. Screening trials aim to create a procedure by which doctors could use a single blood draw to screen for over fifty types of cancer at a time. What's more, this type of screening is ideal for catching fast-growing cancers that other screenings don't detect. Furthermore, other trials are focusing on how to use AI to analyze the result of a blood draw to determine not just if a person has cancer but also what type and the best way to treat it. Unfortunately, screening trials aren't far along enough to recommend MCED testing for the general population, as there is a high false positive rate. Furthermore, extensive additional testing would be required after a positive MCED result to determine if the test was accurate, where the cancer is located, and to identify the best way to treat it. The good news is that ongoing research and screening trials are tackling these issues with the end goal of creating a reliable, effective blood-based screening method that would work for everyone.

Cancer screening trial breakthroughs offer hope that doctors will be able to prevent cancer deaths around the world. When fully developed, new screening technologies would be able to identify who is most likely to develop cancer, pinpoint where this cancer is located, and provide information on the best treatment options. Other ongoing trials using similar methods to cancer screening trials are focused on helping doctors create and track personalized treatment plans to ensure each cancer patient receives the medications and therapies that will work best for him or her personally. Challenges remain, but screening trials have come a long way in overcoming hurdles that make it hard for doctors to catch cancer in patients with few or no symptoms.